Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates-Reference-Cited by-同舟云学术

Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates

Published:2010-08 Issue:8 Volume:10 Page:990-993
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Wagner Doris,Kniepeiss Daniela,Schaffellner Silvia,Jakoby Estrella,Mueller Helmut,Fahrleitner-Pammer Astrid,Stiegler Philipp,Tscheliessnigg Karl-Heinz,Iberer Florian

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference19 articles.

1. Hepatitis C infection in liver transplantation;Charlton;Am J Transplant,2001

2. Hepatitis C: magnitude of the problem;Rakela;Liver Transplant,2002

3. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity;Pelletier;Liver Transplant,2000

4. Long term outcome of hepatitis C infection after liver transplantation;Gane;N Engl J Med,1996

5. Controversies in the management of hepatitis C virus infection after liver transplantation;Shiffman;Liver Transplant,2003

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis;Transplant International;2020-05-15

2. Health Benefits of Anti-aging Drugs;Subcellular Biochemistry;2019

3. Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients;Brazilian Journal of Nephrology;2018-05-14

4. The Role of mTOR Inhibitors in the Management of Viral Infections;Transplantation;2018-02

5. mTOR Inhibition and Clinical Transplantation;Transplantation;2018-02